SCHEMBL712741

SCHEMBL712741

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Oc1ccc2ccc(=O)oc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NDUFS8 O00217 3/20 0.57
COXFA4 O00483 3/20 0.57
NDUFAB1 O14561 3/20 0.57
NDUFA1 O15239 3/20 0.57
NDUFS4 O43181 3/20 0.57
NDUFB5 O43674 3/20 0.57
NDUFB3 O43676 3/20 0.57
NDUFC1 O43677 3/20 0.57
NDUFA2 O43678 3/20 0.57
NDUFS5 O43920 3/20 0.57
NDUFS7 O75251 3/20 0.57
NDUFS2 O75306 3/20 0.57
NDUFS6 O75380 3/20 0.57
NDUFB1 O75438 3/20 0.57
NDUFS3 O75489 3/20 0.57
NDUFB6 O95139 3/20 0.57
NDUFA3 O95167 3/20 0.57
NDUFB4 O95168 3/20 0.57
NDUFB8 O95169 3/20 0.57
NDUFB2 O95178 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12081709 1.00 NDUFS8 (0.57) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL28529405 1.00 NDUFS8 (0.57) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL28061786 0.94 NDUFS8 (0.58) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL13575106 0.91 CA12 (0.54) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL21043916 0.89 CA12 (0.64) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL1095981 0.87 CA12 (0.63) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL19831442 0.87 CA12 (0.63) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL4293165 0.87 CA12 (0.63) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL3469861 0.87 CA12 (0.66) CA12CA9CA1CA6CA7
SCHEMBL3470086 0.86 NDUFS8 (0.53) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767302-B2 Reagents and methods for tetrazine synthesis UNIVERSITY OF DELAWARE (US) 2023-09-26 US disclosed
US-20220106278-A1 REAGENTS AND METHODS FOR TETRAZINE SYNTHESIS UNIVERSITY OF DELAWARE (US) 2022-04-07 US disclosed
US-9168242-B2 Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia UNIGEN, INC. (US) 2015-10-27 US disclosed
US-20140088183-A1 ISOLATION OF A DUAL COX-2 AND 5-LIPOXYGENASE INHIBITOR FROM ACACIA UNIGEN, INC. (US) 2014-03-27 US disclosed
US-8568799-B2 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from acacia UNIGEN, INC. (US) 2013-10-29 US disclosed
US-20120329863-A1 ISOLATION OF A DUAL COX-2 AND 5-LIPOXYGENASE INHIBITOR FROM ACACIA UNIGEN, INC. (US) 2012-12-27 US disclosed
US-8263558-B2 Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins ABBOTT LABORATORIES (US) 2012-09-11 US disclosed
US-8124134-B2 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia UNIGEN, INC. (US) 2012-02-28 US disclosed
US-20090311723-A1 FLUORESCENCE-BASED ASSAY FOR MONOACYLGLYCEROL LIPASE COMPATIBLE WITH INHIBITOR SCREENING WYETH (US) 2009-12-17 US disclosed
US-20090311723-A1 FLUORESCENCE-BASED ASSAY FOR MONOACYLGLYCEROL LIPASE COMPATIBLE WITH INHIBITOR SCREENING WYETH (US) 2009-12-17 US disclosed
US-20090214515-A1 METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-08-27 US disclosed
EP-1963363-A2 METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS Abbott Laboratories (US) 2008-09-03 EP disclosed
WO-2007064917-A2 METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS ABBOTT LABORATORIES (US) 2007-06-07 WO disclosed
US-20060269627-A1 Isolation of a Dual Cox-2 and 5-Lipoxygenase Inhibitor from Acacia UNIGEN PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7108868-B2 Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia UNIGEN PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
EP-1490081-A4 ISOLATION OF A DUAL COX-2 AND 5-LIPOXYGENASE INHIBITOR FROM ACACIA UNIGEN PHARMACEUTICALS INC (US) 2006-04-12 EP disclosed
EP-1490081-A1 ISOLATION OF A DUAL COX-2 AND 5-LIPOXYGENASE INHIBITOR FROM ACACIA Unigen Pharmaceuticals, Inc. (US) 2004-12-29 EP disclosed
WO-2003082312-A1 ISOLATION OF A DUAL COX-2 AND 5-LIPOXYGENASE INHIBITOR FROM ACACIA UNIGEN PHARMACEUTICALS, INC. (US) 2003-10-09 WO disclosed
US-20030180402-A1 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia UNIGEN PHARMACEUTICALS, INC. 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088183-A1 ISOLATION OF A DUAL COX-2 AND 5-LIPOXYGENASE INHIBITOR FROM ACACIA ALOX5, ALOX15, ALOX15B NDUFS8 509/4885COXFA4 123/4885NDUFAB1 602/4885
US-20090311723-A1 FLUORESCENCE-BASED ASSAY FOR MONOACYLGLYCEROL LIPASE COMPATIBLE WITH INHIBITOR SCREENING MGLL, LIPC, LIPA NDUFS8 4473/4885COXFA4 1306/4885NDUFAB1 1629/4885
US-11767302-B2 Reagents and methods for tetrazine synthesis TST, CYP4F8, CYP4Z1 NDUFS8 289/4885COXFA4 1035/4885NDUFAB1 1393/4885
US-20220106278-A1 REAGENTS AND METHODS FOR TETRAZINE SYNTHESIS TST, CYP4F8, CYP4Z1 NDUFS8 289/4885COXFA4 1035/4885NDUFAB1 1393/4885
US-20030180402-A1 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia ALOX5, ALOX5AP, ALOX15 NDUFS8 813/4885COXFA4 119/4885NDUFAB1 601/4885
US-20120329863-A1 ISOLATION OF A DUAL COX-2 AND 5-LIPOXYGENASE INHIBITOR FROM ACACIA ALOX5, ALOX15, ALOX15B NDUFS8 509/4885COXFA4 123/4885NDUFAB1 602/4885
US-20060269627-A1 Isolation of a Dual Cox-2 and 5-Lipoxygenase Inhibitor from Acacia ALOX5, ALOX5AP, ALOX15 NDUFS8 813/4885COXFA4 119/4885NDUFAB1 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.